PA
RLAY icon

Profund Advisors’s Relay Therapeutics RLAY Stock Holding History

Profund Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Buy
88,371
+20,201
+30% +$293K 0.05% 243
2026
Q1 		$678K Sell
68,170
-4,416
-6% -$39.5K 0.02% 456
2025
Q4 		$614K Buy
72,586
+38,886
+115% +$277K 0.02% 489
2025
Q3 		$176K Sell
33,700
-4,923
-13% -$18.8K 0.01% 1002
2025
Q2 		$134K Sell
38,623
-4,306
-10% -$12.8K ﹤0.01% 949
2025
Q1 		$112K Sell
42,929
-5,610
-12% -$22K ﹤0.01% 942
2024
Q4 		$200K Buy
48,539
+12,406
+34% +$67.5K 0.01% 1013
2024
Q3 		$256K Sell
36,133
-285
-0.8% -$2.13K 0.01% 900
2024
Q2 		$237K Sell
36,418
-35,931
-50% -$246K 0.01% 873
2024
Q1 		$600K Buy
72,349
+18,320
+34% +$179K 0.02% 517
2023
Q4 		$595K Sell
54,029
-9,902
-15% -$83.6K 0.03% 463
2023
Q3 		$538K Sell
63,931
-49,182
-43% -$529K 0.03% 452
2023
Q2 		$1.42M Buy
113,113
+30,802
+37% +$383K 0.08% 225
2023
Q1 		$1.36M Buy
+82,311
New +$1.48M 0.08% 211

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Profund Advisors's RLAY Position: Q2 2026 in Review

Profund Advisors increased its Relay Therapeutics (RLAY) stake by 30% in Q2 2026, buying an estimated $293K and bringing the position to 88,371 shares worth $1.65M. The position accounts for 0.05% of the portfolio, ranked #243.

Profund Advisors first reported a position in RLAY in Q1 2023 and has held it in 14 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Profund Advisors held 88,371 shares of Relay Therapeutics worth $1.65M as of Q2 2026.
  • Profund Advisors bought 20,201 Relay Therapeutics shares in Q2 2026, an estimated $293K.
  • Relay Therapeutics made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #243 holding.
  • Profund Advisors first reported a position in Relay Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.